Active Biotech AB Year-end Report January – December 2010

Feb 10, 2011 08:30 (CET) 
· Laquinimod - positive results presented from ALLEGRO Phase III trial

· TASQ - pivotal Phase III study initiated in the first quarter of 2011

· ANYARA - ongoing Phase III study expected to be concluded in 2012

· 57-57 - recommended Orphan Medicinal Product Status

· ISI - project proceeding according to plan

· RhuDex(TM) - preparations for continued clinical development in progress

· Net sales SEK 11.4 M (10.8)

· Operating loss SEK 229.0 M (loss: 219.6)

· Loss after tax SEK 221.1 (loss: 224.0)

· Loss per share for the period amounted to 3.38  (loss: 3.81)

· Private placement of SEK 375 M completed after the end of the period

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam
CFO
Tel. +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com




Active Biotech AB Year-end Report Jan-Dec 2010:
http://hugin.info/1002/R/1487271/422685pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1487271]